Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Di Maio VC, et al. Among authors: parruti g. Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. Liver Int. 2021. PMID: 33497016
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. Svicher V, et al. Among authors: parruti g. Dig Liver Dis. 2010 Dec;42(12):902-7. doi: 10.1016/j.dld.2010.04.017. Epub 2010 Jun 19. Dig Liver Dis. 2010. PMID: 20621632
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Parruti G, Polilli E, Sozio F, Cento V, Pieri A, Di Masi F, Mercurio F, Tontodonati M, Mazzotta E, Ceccherini-Silberstein F, Manzoli L, Perno CF. Parruti G, et al. Antiviral Res. 2010 Oct;88(1):124-7. doi: 10.1016/j.antiviral.2010.08.003. Epub 2010 Aug 11. Antiviral Res. 2010. PMID: 20708036
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
262 results